Similarly, Belarif et al. demonstrated that the expression of the genes associated with the interleukin-7 receptor (IL7R) signalling pathway was altered before treatment in non-responder patients to IFX and VDZ [63], suggesting that IBD patients with altered IL7R expression would benefit more from the use of other biologics or small molecules. The gene discussed is IL7R; the disease is inflammatory bowel disease.